Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FX-8553
- Development stage
- Preclinical
- Lead developer
- Felicitex Therapeutics
- Modality
- Small Molecules
01
Overview
FX-8553 is a preclinical small molecule inhibitor developed by Felicitex Therapeutics for the treatment of glioblastoma. The drug is designed to target quiescent (G0) cancer cells, which are typically resistant to standard therapies like chemotherapy and radiation. By inhibiting kinases that maintain these cells in a dormant state—specifically members of the DYRK (Dual-specificity tyrosine-phosphorylation-regulated kinase) family such as DYRK1A—FX-8553 aims to sensitize the tumor to treatment and reduce the likelihood of recurrence. It is currently being evaluated in preclinical models of glioblastoma multiforme.
02
Targets
DYRK1A (Dual-specificity tyrosine-phosphorylation-regulated kinase 1A)
Beyond the preview
Go deeper on FX-8553.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FX-8553.